These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29 related articles for article (PubMed ID: 29934245)
21. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Arvieux C; Tribut O Drugs; 2005; 65(5):633-59. PubMed ID: 15748098 [TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of selenazole-substituted ritonavir analogs. Qiao J; Zhao C; Liu J; Du Y Bioorg Med Chem Lett; 2018 Aug; 28(14):2379-2381. PubMed ID: 29934245 [TBL] [Abstract][Full Text] [Related]
24. Discovery and clinical development of HIV-1 protease inhibitors. Huff JR; Kahn J Adv Protein Chem; 2001; 56():213-51. PubMed ID: 11329855 [No Abstract] [Full Text] [Related]
25. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine). Arribas JR Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718 [TBL] [Abstract][Full Text] [Related]
26. [Current status of HIV protease inhibitors]. Yang QG; He XC; Bai DL Yao Xue Xue Bao; 2005 May; 40(5):389-94. PubMed ID: 16220778 [No Abstract] [Full Text] [Related]